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Abstract:  
Objective:  To investigate the effectiveness of prophylactic intravenous magnesium sulphate in management of 
pre-eclemptia in terms of prevention from convulsions and developemrnt of eclempsia. Methodology:  This 
prospective randomised trial was conducted in the department of Obtetrical and gynaecology Bahawal Vctoria 
Hospital, Bahawalpur. From September 2016 to September 2017. Information was entered in SPSS computer 
software version 23.1 and analyzed for possible results. Mean and SD was calculated and presented for 
quantitative data like maternal age, Gestational age, Parity and Blood pressure. Frequency (percentages) were 
calculated and presented for qualitative data such as gender protienurea (Yes/No), C-section, development of 
eclempsia and maternal death. Post stratification statistical chi square test was used to see effect modification. P 
value ≤ 0.05 was considered as significant. Results: In this study, a total number of 100% (n=318) patients were 
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included, divided into two equal groups, 159 in each i.e. magnesium sulphate group and placebo group The 
outcomes were observed as Convulsions 2.5% (n=4) and 8.2% (n=13), maternal death1.3% (n=2) and 6.3% 
(n=10), adverse reaction 0.6% (n=1) and 8.2% (n=13), anti-hypertensive therapy 73.6% (n=117) and 81.8% 
(n=130), caesarean Section 59.7% (n=95) and 48.4% (n=77), live births 88.1% (n=140) and 97.5% (n=155) and 
stillbirths 21.4% (n=34) and 12.6% (n=20) for magnesium sulphate group and placebo group respectively. In 
Mgso4 group 95% patients have good efficacy and placebo group have 84.3% good efficacy. Conclusion: 
Relative small incidence of convulsions (2.5%) was found in Mgso4 group, so administration of Magnesium 
sulphate should considered in management of pre-eclempsia. 
 
Introduction: 
Mgso4 is an intravenous or intramuscular agent commonly used in treatment of pre eclemptia or eclemptia as a 
prophylaxis. Mechanism of action of magnesium sulphate in prevention of pre eclempsia is still completely 
unclear (1).  It is claimed that this prevention may be due to the vasodilatation of brain vessels to prevent the 
brain ischemia through which blood pressure become reduced, Mgso4 also involved in peripheral vasodilatation. 
Another thought is that Mgso4 involved in blocking of calcium to altering the neuromuscular transmission by 
inhibiting its entry in synaptic endings. It blocks the action of N-methyl-Daspartate receptors in the brain cells 
(2). 
Round about 40% of plasma Magnesium bound with protein and remaining unbounded Magnesium diffused into 
extracellular across placental barrier in amniotic fluid (3). It also accumulates in bones. When it was given in 
pregnancy, it reaches at its maximum level within fourth and fifth hour of drug administration. Mg eliminated 
through kidneys via urine, almost ninety percent in early 24 hours and remaining slowly in next 24 hours (4).  
Side effects of Magnesium Sulphate are dose depending. Convulsions due to eclemptia can be controlled when 
its concentration reaches at level of 1.8-3.0 mmol/l (5). The real value of mgso4 not estimated yet as prophylaxis. 
Patellar reflux, respiratory paralysis and Cardiac conduction abnormalities are main side effects of mgso4 occurs 
at 3.5-5 mmol/l, 5-6.5 mmol/l and 7.5 mmol/l concentrations respectively (6). It may cause cardiac arrest when 
exceeded 12.5 mmol/l. Its toxicity and side effects are minimum when administered under strict morning.  
Long term use of Mgso4 during gestation may cause hypocalcemia, hypermagnesemia and demineralization in 
fetal skeletal system (7,8). Renal toxicity also reported in these patients, hypo magnesium may lead to 
hypokalemia and cardiac arrhythmias (9). So administration of magnesium must be under observation and 
monitoring of respiratory rate, blood pressure and tendon reflux. Coetzee EJ et al (10) conducted a study on this 
topic and reported in Mgso4 group 0.3% patient’s develop eclempsia and in placebo group 3.2 % patients 
develop eclempsia. 
We conducted this randomized trial to determine the role of magnesium sulphate in management of pre-
eclempsia and study will be used as new gate towards pre-eclempsia management.  
 
Methodology:  
This prospective randomized trial was conducted in the department of Obstetrical and gynecology Bahawal 
Victoria Hospital, Bahawalpur from September 2016 to September 2017. Women of severe eclempsia e admitted 
from outdoor department and antenatal wards of hospital were included in the study by using non probability 
consecutive sampling. Study was started after approval from the institution ethical board and informed consent 
was also obtained from patients. Patients with diastolic blood pressure 110 mmhg and protienurea were 
considered as pre-eclemptic. Efficacy was measured in terms of prevention from convulsions or seizures after 
the use of drug. Women having age less than 16 years and hypertensive disorder were excluded from the study. 
Sample size was obtained by assumption of previous study that P1 in Mgso4 group 0.3% patients develop 
eclempsia but P2 in placebo group 3.2 % patients develop eclempsia; CI 95%, power 80% and calculated sample 
size was 318 patients. 
Sealed envelopes were divided to the patients, each envelope consist of a card directing to the use of solution A 
and B. Cards have consecutive numbers and envelopes were divided into patients randomly. Solutions were 
made by a third person (4g of Mgso4 in 200 ml N/S and 200 ml N/S only).Identification of the solutions altered 
randomly without information to the researcher and at the end of study solutions were exposed. 
Routine investigations (urea, creatinine, complete blood count, serum electrolytes) were done except serum Mg 
level. All women were observed under special monitoring for of blood pressure, and urine output. Desired level 
of blood pressure (diastolic 100-110 mmhg) was achieved where it is necessary by giving 25 dihydralazine i/v 
infusion in 200 ml N/S. After keeping the patient stable labour was induced artificially or delivered through C-
section.  
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Collected Information was entered in SPSS computer software version 23.1 and analyzed for possible results. 
Mean and SD was calculated and presented for quantitative data like maternal age, Gestational age, Parity and 
Blood pressure. Frequency (percentages) were calculated and presented for qualitative data such as gender 
protienurea (Yes/No), C-section, development of eclempsia, maternal death and efficacy. Post stratification 
statistical chi square test was used to see effect modification. P value ≤ 0.05 was considered as significant.  
 
Results: 
In this study, a total number of 100% (n=318) patients were included, divided into two equal groups, 
159 in each i.e. magnesium sulphate group and placebo group. The Mean±S.D maternal age, parity, gestational 
age, birth weight, systolic blood pressure, diastolic blood pressure and model proteinuria (+) of the patients of 
group magnesium sulphate was 23.05±2.18 years, 0.08±0.405 parity, 34.94±3.57 weeks, 2119.13±24.61 g, 
173.77±4.51 (mmHG), 118.64±3.80 (mmHG), 3.50±0.50 respectively. While, the Mean±S.D maternal age, 
parity, gestational age, birth weight, systolic blood pressure, diastolic blood pressure and model proteinuria (+) 
of the patients of group magnesium sulphate was 26.16±4.15 years, 0.04±0.22 parity, 35.86±1.17 weeks, 
2244.33±68.83 g, 178.70±9.64 (mmHG), 118.36±2.33 (mmHG), 4.94±1.20 respectively. No. twin pregnancies 
was observed as 3.1% (n=5) and 6.3% (n=10) in magnesium sulphate group and placebo group respectively. 
Symptoms of imminent eclempsia were noted 58.5% (n=93) and 62.3% (n=99) for magnesium sulphate group 
and placebo group respectively. (Table. 1) 
The outcomes were observed as Convulsions 2.5% (n=4) and 8.2% (n=13), maternal death1.3% (n=2) 
and 6.3% (n=10), adverse reaction 0.6% (n=1) and 8.2% (n=13), anti-hypertensive therapy 73.6% (n=117) and 
81.8% (n=130), caesarean Section 59.7% (n=95) and 48.4% (n=77), live births 88.1% (n=140) and 97.5% 
(n=155) and stillbirths 21.4% (n=34) and 12.6% (n=20) for magnesium sulphate group and placebo group 
respectively. (Table. 2).  In Mgso4 group 95% patients have good efficacy and placebo group have 84.3% 
(n=134) good efficacy, this difference was statistically significant (p=0.002). (Table-2).  
Association was found between maternal age (p=0.000), gestational age (p=0.002), birth weight 
(p=0.000), systolic blood pressure (p=0.000) and Modal proteinuria (+) (p=0.000). (Table. 1). There were 
statistically significant differences in women receiving placebo or magnesium sulphate solution intravenously, 
apart from the incidence of eclempsia. After applying chi-square. (Table. 2).  
 
Table-1: Demographic Variables 
Variable Magnesium Sulphate 
(n=159) 
Placebo 
 (n=159) 
Test of Sig. 
Maternal age 23.05±2.18 years 26.16±4.15 years t=-8.36,p=0.000 
Parity 0.08±0.405 parity 0.04±0.22 parity t=1.20,p=0.230 
Gestational age (weeks) 34.94±3.57 weeks 35.86±1.17 weeks t=-3.06,p=0.002 
Birth weight (g) 2119.13±24.61 g 2244.33±68.83 g t=-21.60,p=0.000 
Systolic blood pressure 173.77±4.51(mmHG) 178.70±9.64(mmHG) t=-5.84,p=0.000 
Diastolic blood pressure 118.64±3.80(mmHG) 118.36±2.33(mmHG) t=0.799,p=0.425 
Modal proteinuria (+) 
3.50±0.50 4.94±1.20 t=-13.85,p=0.000 
Symptoms of imminent 
eclampsia 
58.5% (n=93) 62.3% (n=99) χ
2 
=473,p=0.492 
No. twin pregnancies 3.1% (n=5) 6.3% (n=10) χ
2 =1.75,p=0.186 
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Table-2: Inferential Results (Outcomes) 
Variable Magnesium Sulphate 
(n=159) 
Placebo 
 (n=159) 
Test of Sig. 
Convulsions 2.5% (n=4) 8.2% (n=13) χ
2 
=5.034,p=0.025 
Efficacy 
Good 
95 % (n=151) 84.3% (n=134) 
χ
2 
=9.772,p=0.002 
Poor 5% (n=8) 15.7% (n=25) 
 
Table-3: Effect Modifiers of study 
Maternal death 1.3% (n=2) 6.3% (n=10) χ
2 =5.542,p=0.019 
Adverse reaction 0.6% (n=1) 8.2% (n=13) χ
2 
=10.76,p=0.001 
Anti-hypertensive therapy 73.6% (n=117) 81.8% (n=130) χ
2 
= 7.825,p=0.005 
Caesarean Section 59.7% (n=95) 48.4% (n=77) χ
2 
=4.103,p=0.043 
Live births 88.1% (n=140) 97.5% (n=155) χ
2 =10.55,p=0.001 
Stillbirths 21.4% (n=34) 12.6% (n=20) χ
2 
=4.372,p=0.037 
 
 
Discussion: 
Results of study revealed that use of magnesium sulphate in pre-eclemptic phase save the patient from 
complications of eclempsia. Its use in all cases of pre-eclempsia and daily use is not justified yet, in milder cases 
it is useful but in severe cases its use is not usefull and side effects of magnesium sulphate should be kept in 
mind before its administration (11). Close monitoring also reduce its incidence Sibai et al  (12)recommended its 
doses 1 g/hour , 2-3 g/ hour can also be administered but without margin of safety. A recent trial was conducted 
on this topic of efficacy of Mgso4 and reported that our women are reluctant to use of placebo and it is 
considered as unethical in our society. 
Burrows and Burrows et al  (13) conducted a similar study and reported 1.3 % incidence of eclempsia in placebo 
group and justified the use of placebo which is much lower percentage, these finding are compareable with our 
finding in a study by Coetzee EJ et al (10) reported 3.2 % incidence in placebo group. This percentage is close to 
our results. 
Chien et al (14) conducted a randomized control trial between placebo and Mgso4 in management of eclempsia 
and pre eclempsia and concluded that Mgso4 is very effective in the management of convulsions due to 
eclempsia and Mgso4 can be used in eclemptic patients but this study was conducted on sample size trials on 
larger scale are required for complete and definite treatmet. These results are also identical to our results. 
In an another trial by Duley and Johnson et al (15) same results were reported that for the management of pre-
eclempsia with Mgso4 recommendations require larger scale studies more precisely. Sample size of this trial 
should be at least 1200 or more. Lucas et al (16) conducted a study on comparison of Mgso4 and phenytoin in 
management of eclempsia. This study was on larger scale about 2138 patients included and reported no case of 
eclempsia in magnesium sulphate group but phenytoin group have almost ten women who develop convulsion of 
eclempsia. All patients of mild to severe disease and with or without protienturia were selected for this trial.  
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There is another trial by Roberts et al (17) concluded that there may be some other beneficial effects of Mgso4 
for but in management of convulsion and seizures role of Mgso4 is outstanding, convulsions are very rare after 
use of Mgso4 in pre-eclemptic phase. But in our trial we didn’t evaluate its beneficial effects. There were lot of 
other factors which can cause convulsions and eclempsia, all selected women should be given clonazepam and 
antihypertensive medication at the time of admission and monitored under intensive care with all essential 
monitoring systems (18, 19). Eclempsia and pre eclempsia may lead to hemorrhage, cerebral infarctions and may 
be death. It causes vasoconstriction of relevant area and results into ischemia or stroke. Magnesium sulphate 
found to be drug of choice in many studies for the management of pre-eclempsia (20). 
 
Conclusion: Relative small incidence of convulsions (2.5%) was found in Mgso4 group, so administration of 
Magnesium sulphate should considered in management of pre-eclempsia. 
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